Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
APILAM informs you that the personal data that you provide to us by filling in this form will be treated by APILAM as responsible for this web.
The purpose of the collection and processing of personal data that we request is to manage the registration of this subscription and send periodic bulletins with information and prospective offer of products or services.
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product. Former level of risk, which was Low Risk, is now set to Very Low Risk.
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product. Former level of risk, which was Low Risk, is now set to Very Low Risk.
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product. Former level of risk, which was Low Risk, is now set to High Risk.
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product. Former level of risk, which was Low Risk, is now set to High Risk.
